Shares of Ajanta Pharma Ltd were in focus on Wednesday after promoter entity Ravi Agrawal Trust sold 34.5 lakh shares, representing a 2.8 percent stake, in a transaction valued at about Rs 1,024 crore.
The stock rose as much as 1.9 percent during the session to Rs 3,070.35, against the previous close of Rs 3,012.15. The company commands a market capitalization of Rs 38,217.18 crore.
Mutual funds emerge as buyers
The block deal was executed at an average price of Rs 2,968 per share.
The buyers included:
- Kotak Mahindra Mutual Fund, which purchased 21 lakh shares worth around Rs 624 crore.
- Aditya Birla Sun Life Mutual Fund, which acquired 13.5 lakh shares valued at nearly Rs 400 crore.
The seller in the transaction was Ravi Agrawal Trust, one of the promoter entities of the company.
Quarterly performance
Ajanta Pharma reported higher revenue and profit in the latest quarter.
Revenue increased by 21.47 percent to Rs 1,422 crore in March 2026, compared with Rs 1,170 crore in March 2025.
Net profit rose to Rs 267 crore, up from Rs 225 crore a year earlier.
Financial metrics
The company continues to maintain strong profitability and low leverage.
Key ratios include:
- ROCE: 32.3 percent
- ROE: 25.4 percent
- Debt-to-equity ratio: 0.06
Capex plans
Management has guided capital expenditure of Rs 330 crore for FY26.
Capex is expected to increase to around Rs 400 crore in FY27.
The proposed spending includes:
- Rs 150 crore towards maintenance capex.
- Rs 250 crore towards growth capex.
The expansion will be carried out at existing facilities, where the company already has sufficient land available.
Growth outlook
Management has guided for revenue growth in the high teens, which translates to around 16-18 percent at current exchange rates.
About the company
Founded in 1973 and headquartered in Mumbai, Ajanta Pharma Ltd develops, manufactures and markets specialty branded generics and generic pharmaceutical products.
The company has a strong presence in India and emerging markets across Asia and Africa.
Its key therapeutic segments include:
- Cardiology
- Dermatology
- Ophthalmology
- Pain management
Ajanta Pharma focuses on differentiated and niche products and continues to invest in research and development to strengthen its portfolio.
TL;DR
Ajanta Pharma shares were in focus after promoter entity Ravi Agrawal Trust sold a 2.8 percent stake worth Rs 1,024 crore. Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund purchased the shares through block deals executed at Rs 2,968 apiece.
AI Summary
- Ravi Agrawal Trust sold a 2.8 percent stake in Ajanta Pharma.
- The transaction was valued at Rs 1,024 crore.
- Kotak Mahindra Mutual Fund bought shares worth Rs 624 crore.
- Aditya Birla Sun Life Mutual Fund acquired shares worth Rs 400 crore.
- Revenue and net profit rose 21.47 percent and 18.7 percent, respectively, in the latest quarter.
